COLUMBUS, Ohio - Denis Guttridge, PhD, has been named associate director for basic research at The Ohio State University Comprehensive Cancer Center (OSUCCC) effective Feb. 1, 2017.
In this role, Guttridge will be responsible for coordinating basic science across the OSUCCC research programs, with a focus on fostering existing and building new collaborative efforts. At Ohio State, this includes more than 300 cancer researchers and their teams from 12 of the university’s 15 colleges who work collaboratively across disciplines to conduct cancer research aimed at improving the effectiveness of cancer prevention, diagnosis and treatment.
Guttridge most recently served as co-leader of the Molecular Carcinogenesis and Chemoprevention Program at the OSUCCC, a role he will transition out of once he becomes the associate director for basic research.
“We are excited to have Denis is this expanded leadership role. He is a driven scientist and strong mentor to junior faculty. He has played a number of important roles within our cancer center, and I have no doubt he will continue to contribute in a big way to our vision of creating a cancer-free world,” said Michael Caligiuri, MD, director of the OSUCCC and chief executive officer of the James Cancer Hospital and Solove Research Institute.
Guttridge is a professor in The Ohio State University College of Medicine Department of Cancer Biology and Genetics. He is also principal investigator for multiple National Institutes of Health (NIH) research project grants and an NIH research-training grant. His research focuses on the NF-kB family of transcription factors, and the role these molecules play in cell growth and differentiation. His specific interests are cancer cachexia and pancreatic cancer, and muscle disorders such as muscular dystrophy and rhabdomyosarcoma.
Guttridge holds a doctoral degree in biological sciences from The University of California – Irvine and a master’s degree in biochemistry from California State University. He performed his Postdoctoral Fellowship at the Lineberger Cancer Center at the University of North Carolina, Chapel Hill.
To learn more about the OSUCCC – James, visit cancer.osu.edu.
About the OSUCCC – James
The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute strives to create a cancer-free world by integrating scientific research with excellence in education and patient-centered care, a strategy that leads to better methods of prevention, detection and treatment. Ohio State is one of only 49 National Cancer Institute-designated Comprehensive Cancer Centers and one of only a few centers funded by the NCI to conduct both phase I and phase II clinical trials on novel anticancer drugs. As the cancer program’s 306-bed adult patient-care component, The James is one of the top cancer hospitals in the nation as ranked by U.S. News & World Report and has achieved Magnet designation, the highest honor an organization can receive for quality patient care and professional nursing practice. At 21 floors with more than 1.1 million square feet, The James is a transformational facility that fosters collaboration and integration of cancer research and clinical cancer care. For more information, please visit cancer.osu.edu.